Market revenue in 2023 | USD 80.8 million |
Market revenue in 2030 | USD 382.0 million |
Growth rate | 24.8% (CAGR from 2023 to 2030) |
Largest segment | Hemp |
Fastest growing segment | Hemp |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hemp, Marijuana |
Key market players worldwide | Medical Marijuana Inc, Canopy Growth Corp, Elixinol Wellness Ltd Ordinary Shares, The Cronos Group, Isodiol International Inc, Endoca, Folium Biosciences, NuLeaf Naturals, PharmaHemp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cannabidiol market will help companies and investors design strategic landscapes.
Hemp was the largest segment with a revenue share of 53.22% in 2023. Horizon Databook has segmented the Switzerland cannabidiol market based on hemp, marijuana covering the revenue growth of each sub-segment from 2018 to 2030.
Switzerland is considered one of the most progressive countries in Europe. The Swiss laws on cannabis possession and consumption have been relatively relaxed. In Switzerland, prevention and treatment are prioritized over the criminalization of users. Though medical cannabis is illegal in Switzerland, minor possession (less than 10 grams) was decriminalized with the levy of a small fine.
As CBD does not produce any psychoactive effect, it is not subject to the Narcotics Act (NarcA, CC 812.121). However, CBD products can be legally marketed only if they comply with the legislation of the country. In Switzerland, products containing CBD are gaining popularity. The suppliers in the market are offering a wide range of CBD-containing products using various distribution channels to satisfy customer demand.
In August 2022, Switzerland launched Europe's first cannabis sales pilot program, becoming the first European country to do so. The program, known as “Weed Care,” commenced in September 2022 and would run for two and a half years, concluding in March 2025. The program is designed to study the effects of cannabis legalization.
Horizon Databook provides a detailed overview of country-level data and insights on the Switzerland cannabidiol market , including forecasts for subscribers. This country databook contains high-level insights into Switzerland cannabidiol market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account